Marinus PharmaceuticalsMRNS
MRNS
About: Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Employees: 166
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
176% more call options, than puts
Call options by funds: $398K | Put options by funds: $144K
45% more capital invested
Capital invested by funds: $50.9M [Q2] → $73.5M (+$22.7M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3.99% less ownership
Funds ownership: 79.09% [Q2] → 75.1% (-3.99%) [Q3]
16% less funds holding
Funds holding: 90 [Q2] → 76 (-14) [Q3]
26% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 27
54% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 26
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$0.50
117%
upside
Avg. target
$3.69
1,503%
upside
High target
$10
4,248%
upside
8 analyst ratings
5 positive
63%
3 neutral
38%
0 negative
0%
Cantor Fitzgerald Charles Duncan 43% 1-year accuracy 35 / 82 met price target | 1,639%upside $4 | Overweight Reiterated | 14 Nov 2024 |
HC Wainwright & Co. Douglas Tsao 43% 1-year accuracy 71 / 167 met price target | 770%upside $2 | Neutral Reiterated | 14 Nov 2024 |
D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 1,204%upside $3 | Buy Maintained | 13 Nov 2024 |
RBC Capital Brian Abrahams 19% 1-year accuracy 15 / 79 met price target | 335%upside $1 | Sector Perform Maintained | 25 Oct 2024 |
Jefferies Andrew Tsai 20% 1-year accuracy 1 / 5 met price target | 117%upside $0.50 | Hold Downgraded | 25 Oct 2024 |
Financial journalist opinion
Negative
Zacks Investment Research
1 month ago
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago.
Neutral
Business Wire
1 month ago
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. “We are pleased to see continued commercial growth of ZTALMY with more than 200 patients active on therapy and a steady increase in demand,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of.
Neutral
Business Wire
1 month ago
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency. While reductions in seizure frequency fav.
Neutral
Business Wire
2 months ago
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS) Annual Meeting. Topline data demonstrating that the trial met one of two co-primary endpoints were reported in June.
Positive
Benzinga
2 months ago
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory.
Neutral
Business Wire
2 months ago
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has added to its intellectual property (IP) estate with a new patent issued by the United States Patent and Trademark Office (USPTO) for ZTALMY® (ganaxolone) oral titration regimens covering the treatment of a range of epilepsy disorders, including CDKL5 deficiency disorder, tuberous sclerosis.
Positive
MarketBeat
2 months ago
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory.
Neutral
Business Wire
2 months ago
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that additional data from the Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data from patients with status epilepticus will be presented at the upcoming Neurocritical Care Society (NCS) 22nd Annual Meeting, being held October 14-17 in San Diego, California. Pr.
Neutral
Business Wire
2 months ago
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 9,800 shares of its common stock (the “Common Stock”) as inducements material to the employees entering.
Positive
Benzinga
2 months ago
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Marinus Pharmaceuticals MRNS is a micro-cap pharmaceutical stock with multiple Wall Street analysts seeing significant upside. Both Oppenheimer and Cantor Fitzgerald recently issued or reiterated massive price targets for the company.
Charts implemented using Lightweight Charts™